click below
click below
Normal Size Small Size show me how
Musculoskeletal
MUSCULOSKELETAL 1-2
Generic Name | Brand Name | Pharmacological Category | Common Indications | Key Side Effects | US Boxed Warnings | Other Notes |
---|---|---|---|---|---|---|
colchicine (PO) | Colcrys | Antigout agent | Gout | diarrhea, nausea, vomiting, bone marrow suppression, myotoxicity (including rhabdomyolysis) | ||
diclofenac (PO) | Voltaren | NSAID | OA, RA, acute pain | diarrhea, dyspepsia, abdominal pain, flatulence, nausea | may increase the risk of serious (and potentially fatal) cardiovascular thrombotic events; may increase the risk for serious (and potentially fatal) gastrointestinal adverse events including ulceration, bleeding, and perforation | may reduce renal blood flow and compromise existing renal function (avoid in patients with renal disease, heart failure, and cirrhosis) |
ibuprofen (PO) | Motrin, Advil | NSAID | OA, RA, acute pain | diarrhea, dyspepsia, abdominal pain, flatulence, nausea | may increase the risk of serious (and potentially fatal) cardiovascular thrombotic events; may increase the risk for serious (and potentially fatal) gastrointestinal adverse events including ulceration, bleeding, and perforation | may reduce renal blood flow and compromise existing renal function (avoid in patients with renal disease, heart failure, and cirrhosis) |
meloxicam (PO) | Mobic | NSAID | OA, RA, acute pain | diarrhea, dyspepsia, abdominal pain, flatulence, nausea | may increase the risk of serious (and potentially fatal) cardiovascular thrombotic events; may increase the risk for serious (and potentially fatal) gastrointestinal adverse events including ulceration, bleeding, and perforation | may reduce renal blood flow and compromise existing renal function (avoid in patients with renal disease, heart failure, and cirrhosis) |
nabumetone (PO) | Relafen | NSAID | OA, RA, acute pain | diarrhea, dyspepsia, abdominal pain, flatulence, nausea | may increase the risk of serious (and potentially fatal) cardiovascular thrombotic events; may increase the risk for serious (and potentially fatal) gastrointestinal adverse events including ulceration, bleeding, and perforation | may reduce renal blood flow and compromise existing renal function (avoid in patients with renal disease, heart failure, and cirrhosis) |
piroxicam (PO) | Feldene | NSAID | OA, RA, acute pain | diarrhea, dyspepsia, abdominal pain, flatulence, nausea | may increase the risk of serious (and potentially fatal) cardiovascular thrombotic events; may increase the risk for serious (and potentially fatal) gastrointestinal adverse events including ulceration, bleeding, and perforation | may reduce renal blood flow and compromise existing renal function (avoid in patients with renal disease, heart failure, and cirrhosis) |
indomethacin (PO) | Indocin | NSAID | OA, RA, acute pain, gout | diarrhea, dyspepsia, abdominal pain, flatulence, nausea | may increase the risk of serious (and potentially fatal) cardiovascular thrombotic events; may increase the risk for serious (and potentially fatal) gastrointestinal adverse events including ulceration, bleeding, and perforation | may reduce renal blood flow and compromise existing renal function (avoid in patients with renal disease, heart failure, and cirrhosis) |
naproxen (PO) | Naprosyn, Anaprox | NSAID | OA, RA, acute pain, gout | diarrhea, dyspepsia, abdominal pain, flatulence, nausea | may increase the risk of serious (and potentially fatal) cardiovascular thrombotic events; may increase the risk for serious (and potentially fatal) gastrointestinal adverse events including ulceration, bleeding, and perforation | may reduce renal blood flow and compromise existing renal function (avoid in patients with renal disease, heart failure, and cirrhosis) |
ketorolac (PO, IV) | Toradol | NSAID | Pain | diarrhea, dyspepsia, abdominal pain, flatulence, nausea | indicated for short term use (≤ 5 days) | may reduce renal blood flow and compromise existing renal function (avoid in patients with renal disease, heart failure, and cirrhosis) |
celecoxib (PO) | Celebrex | NSAID, COX-2 selective | OA, RA, acute pain | diarrhea, dyspepsia, abdominal pain, flatulence, nausea | may increase the risk of serious (and potentially fatal) cardiovascular thrombotic events; may increase the risk for serious (and potentially fatal) gastrointestinal adverse events including ulceration, bleeding, and perforation | may reduce renal blood flow and compromise existing renal function (avoid in patients with renal disease, heart failure, and cirrhosis) |
diclofenac (topical) | Voltaren Gel, Solareze | NSAID | OA | pruritus, rash | ||
cyclobenzaprine (PO) | Flexeril | Skeletal muscle relaxant | Muscle spasm | drowsiness, dizziness, xerostomia, fatigue | use may cause prolonged cardiac, arrhythmias, and tachycardia; CI within 14 days of MAOI inhibitor therapy | |
baclofen (PO) | Lioresal | Skeletal muscle relaxant | Spasticity | drowsiness | ||
carisoprodol (PO) | Soma | Skeletal muscle relaxant | Muscle spasm | drowsiness | drug abuse potential (carisoprodol only) | |
methocarbamol (PO) | Robaxin | Skeletal muscle relaxant | Muscle spasm | drowsiness | ||
metaxalone (PO) | Skelaxin, Metaxall | Skeletal muscle relaxant | Muscle spasm | drowsiness | ||
orphenadrine (PO) | Norflex | Skeletal muscle relaxant | Muscle spasm | drowsiness, dizziness, xerostomia, fatigue | use caution in patients with cardiac disease | |
bupivacaine (IV) | Marcaine, Sensorcaine | Local anesthetic | Epidural anesthesia | hypotension | bupivacaine 0.75% should not be used for obstetrical anesthesia due to reports of cardiac arrest and death | ISMP-high alert medication |
lidocaine (transdermal, IV) | Transdermal: Lidoderm IV: Xylocaine | Transdermal: topical analgesic IV: antiarrhythmic | Transdermal: pain IV: ventricular arrhythmias | dermatitis, erythema, urticaria, skin depigmentation, skin edema | bradycardia | ISMP-high alert medication (IV), patch may remain in place for up to 12 hours in any 24-hour period, patch may be cut |
allopurinol (PO) | Zyloprim | Xanthine oxidase Inhibitor | Gout | diarrhea, nausea, rash, leukopenia, thrombocytopenia | rare association with severe (and potentially fatal) allopurinol hypersensitivity syndrome (risk highest in certain Asian populations) | |
succinylcholine (IV) | Anectine | Depolarizing neuromuscular blocking agent | Neuromuscular blockade for intubation or procedures | hyperkalemia, myalgia, malignant hyperthermia (rare) | acute rhabdomyolysis and hyperkalemia leading to cardiac arrest and death in pediatric patients with undiagnosed skeletal muscle disease | ISMP-high alert medication |
tizanidine (PO) | Zanaflex | Alpha2 agonist | Spasticity | drowsiness, hypotension, dizziness, xerostomia, weakness | ||
hydroxychloroquine (PO) | Plaquenil | Aminoquinoline | RA, SLE, malaria | retinal toxicity, rash, diarrhea | use has been associated with cardiomyopathy, bone marrow suppression, and neuromuscular effects (i.e., myopathy, palsies, and progressive weakness) |